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Background: 
Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible and ultimately fatal disease.  An 
association between diabetes, obesity and IPF has previously been demonstrated (1). Decreasing body 
mass index (BMI) is predictive of worse survival in Japanese cohorts (2). 
Objective: 
To investigate the metabolic characteristics in our cohort of IPF patients (South West Peninsula, 
England) receiving anti-fibrotic therapy (nintedanib or pirfenidone), observe how BMI changes over 
time and relationships with changes in forced vital capacity (FVC) and survival. 
Method: 
Data was collected from IPF patients at the Regional Exeter ILD Centre at diagnosis (age, gender, FVC, 
BMI, co-morbidities) and subsequent appointments (FVC and BMI). Change between BMI/FVC at 
diagnosis and most recent BMI/FVC were calculated and standardised to time elapsed between data 
points (BMI or FVC respectively). National data were from Public Health England (2014 datasets). 
Results: 
We reviewed 90 patients receiving antifibrotics. 76 were male (84%), mean age was 74. Their co-
morbidities are illustrated by table 1. Type 2 diabetes mellitus affected 14 patients (16%), compared 
with 12% in the age-adjusted general population. Recent BMIs were available for 46 patients. 10 
patients (20%) had a normal BMI 18.5-24.99 (compared with a national average of 37%). Mean BMI 
(28.3) was significantly increased above the national average (27.3; p<0.05 one-tailed t-test).  
Pearson correlation coefficient for change in BMI and survival was r= -0.55, 95% confidence interval -
0.90 to 0.25 (8 patients). Where BMI and FVC were temporally overlapping (19 patients), no 
correlation was found.  
Conclusions: 
A large proportion of our IPF cohort were classified as obese. Diabetes was a common comorbidity, 
and higher than the national average.  Over time, most patients demonstrated a reduction in their 
BMI. In contrast to East Asian data, this reduction in BMI did not correlate with reduction in FVC or 
survival. 
IPF patients n=90 
Age (years) (SD) 74 (9) 
Gender, male 76 (84%) 
Current Treatment n=90 
Nintedanib 55 (61%) 
Pirfenidone 35 (39%) 
Comorbidities  
Ischaemic heart disease 23 (26%) 




Type 2 Diabetes Mellitus 14 (16%) 
Osteoarthritis 9 (10%) 
Hypothyroidism 7 (8%) 
Hypercholesterolaemia 6 (7%) 
Asthma 5 (6%) 
Inflammatory bowel disease 3 (3%) 
Other connective tissue disease 3 (3%) 
Gout 3 (3%) 
Chronic Kidney disease 2 (2%) 
Obstructive sleep apnoea 1 (1%) 
  
WHO BMI Classification n=46 
Underweight (<18.5) 0 
Normal (18.5 - 24.99) 10 (22%) 
Pre-obese (25-29.99) 17 (37%) 
Obese Class 1 or 2 (30-39.99) 18 (39%) 
Obese Class 3 (>40) 1 (2%) 
 
Delta BMI  
(change in BMI per month) n=43 
Median (SD) -0.05 (0.2) 
Range -0.41 to +0.63 per month 
 
Delta FVC 
(Change in FVC per month) n=44 
Median (SD) -0.3% (0.81%) 
Range -2.44% to +1.5% 
  
 
Table 1: Characteristics of the Exeter IPF cohort. SD = standard devation 
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